Cargando…
“Real world effectiveness of cerliponase alfa in classical and atypical patients. A case series”
INTRODUCTION: Late infantile neuronal ceroid lipofuscinosis is an autosomal recessive disease caused by mutations in the CLN2/TPP1 gene, with secondary enzyme deficiency. In classical phenotypes, initial symptoms include seizures and delayed language development between 2 and 4 years of age. This ar...
Autores principales: | Espitia Segura, O.M., Hernández, Z., Mancilla, N.I., Naranjo, R.A., Tavera, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873677/ https://www.ncbi.nlm.nih.gov/pubmed/33604240 http://dx.doi.org/10.1016/j.ymgmr.2021.100718 |
Ejemplares similares
-
Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series
por: Wibbeler, Eva, et al.
Publicado: (2020) -
Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa
por: Schaefers, J., et al.
Publicado: (2021) -
Cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease
Publicado: (2019) -
Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration
por: Kim, Aryun, et al.
Publicado: (2020) -
Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment
por: Mortensen, Amanda, et al.
Publicado: (2022)